Omar Elghawanmeh, MD
Neurology · Ashland, KYNPI 1386873073
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $108,040 of the $121,842 with a category attached, or 88.7%. 31 manufacturers reported payments, led by AbbVie at 35.7% of the total. Reporting peaked in 2021 at $48,287 and has fallen 84.9% since, to $7,281 in 2025. Among neurology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 779 payments — averaging $156.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$44K
- Biohaven Pharmaceuticals, Inc.$34K
- Biohaven Pharmaceutical Holding Company Ltd.$33K
- Livanova USA, Inc.$7K
- Lilly USA, LLC$808
- Supernus Pharmaceuticals, Inc.$688
- plus $3K from 25 others
What the payments were for
- Speaking & faculty fees$108,04089%
- Travel & lodging$2,8692%
- Food & beverage$10,8899%
- Education$440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 365 | $43,522 |
| Biohaven Pharmaceuticals, Inc. | 60 | $33,851 |
| Biohaven Pharmaceutical Holding Company Ltd. | 67 | $33,081 |
| Livanova USA, Inc. | 15 | $6,702 |
| Lilly USA, LLC | 38 | $808 |
| Supernus Pharmaceuticals, Inc. | 67 | $688 |
| Pfizer | 37 | $403 |
| Biogen | 21 | $386 |
| Lundbeck LLC | 10 | $381 |
| Novartis | 13 | $269 |
| Argenx US, Inc. | 10 | $248 |
| Neurocrine Biosciences, Inc. | 8 | $245 |
| Sunovion Pharmaceuticals Inc. | 15 | $239 |
| Amgen | 12 | $235 |
| Sumitomo Pharma America, Inc. | 8 | $125 |
| Teva Pharmaceuticals USA, Inc. | 5 | $86 |
| Acadia Pharmaceuticals Inc | 4 | $80 |
| SK Life Science, Inc. | 4 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $65 |
| Johnson & Johnson | 2 | $50 |
| Neurelis, Inc. | 2 | $47 |
| Kyowa Kirin, Inc. | 2 | $46 |
| Abbott | 2 | $39 |
| MDD US Operations, LLC | 2 | $37 |
| Eisai Inc. | 1 | $23 |
| Merz Pharmaceuticals, LLC | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Si-bone, Inc. | 1 | $17 |
| Ceribell, Inc. | 1 | $16 |
| EMD Serono, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$66,373
- UBRELVY$35,576
- QULIPTA$15,790
- VNS Therapy$6,384
- INGREZZA$134
- EMGALITY$113
- REYVOW$113
How this compares
$121,842 in reported general payments places this provider in the 95th percentile of 210 neurology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 121 | $173,180 |
| Nurtec OdtRimegepant Sulfate | 55 | $79,413 |
| Emgality PenGalcanezumab-Gnlm | 77 | $77,370 |
| BotoxOnabotulinumtoxina | 61 | $76,459 |
| Aimovig AutoinjectorErenumab-Aooe | 56 | $63,757 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 46 | $45,719 |
| BriviactBrivaracetam | 13 | $18,639 |
| Trokendi XrTopiramate | 16 | $18,631 |
| Emgality SyringeGalcanezumab-Gnlm | 15 | $17,065 |
| QuliptaAtogepant | 15 | $16,760 |
| Levetiracetam | 268 | $8,056 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 14 | $6,935 |
| Oxcarbazepine | 135 | $6,026 |
| Duloxetine Hcl | 261 | $3,504 |
| Gabapentin | 137 | $3,478 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Botox, Qulipta | $43,522 | $266,399197 claims |
| PfizerNurtec Odt | $403 | $79,41355 claims |
| Supernus Pharmaceuticals, Inc.Trokendi Xr | $688 | $18,63116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 210 neurology providers in Kentucky.
Other neurology in Ashland
- James WinkleyLexington$807K
- Nicole EvermanLexington$355K
- Toufic FakhouryLexington$278K
- Brian PlatoLouisville$232K
- Kristi NordLouisville$217K
- Naveed AhmedPikeville$215K
- Angela HardwickLouisville$187K
- Peter HederaLouisville$185K
- Jeffrey FrankLouisville$181K
- Joseph OwensPrestonsburg$141K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.